Bipolar affective disorder occurring with psychopharmacotherapy-induced manic phases

Close metadata

Recommended articles:

Atypical antipsychotics in the treatment of depression in affective disorders and schizophrenia (using the aripiprazole model). S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):36-42

Features of cognitive impairment in bipolar affective disorder. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):15-19

Growth factors PDGF-AA, PDGF-BB and BDNF as potential differentiating biomarkers of unipolar and bipolar depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):104-108

The gut microbiota in bipolar disorder. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):28-33

Comparative study of cognitive impairment in subgroups of bipolar affective disorder types I and II, occurring with and without psychotic symptoms. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):7-11

To analyze the stages of development of the problem, identify the evolution of views and the main directions of current research in the field of bipolar affective disorder, which occurs with psychopharmacotherapy-induced manic phases, the search for publications by keywords «pharmaco-induced mania»”, «bipolar affective disorder» was carried out in the PubMed/MEDLINE, Russian Citation index and other sources from the mid-19^th century to the present. The issue of adequate treatment of bipolar depression became relevant back in the 20^th century; numerous observations indicated the presence of associated risks when using antidepressants in patients with bipolar affective disorder, namely, the likelihood of affect inversion and aggravation of the course of the disease (accelerated cyclicity, continuum). In recent years, due to the expansion of research capabilities and the introduction of biological psychiatry, works have appeared that consider this problem from both clinical and pharmacodynamic, genetic and neurophysiological aspects, which opens up the prospect of developing advanced methods of personalized medicine for the diagnosis and treatment of bipolar disorder, taking into account the need to minimize iatrogenic effects.

Keywords:

bipolar affective disorder

pharmaco-induced mania

affect inversion

Authors:

Shteinberg A.S.

Mental Health Research Centre

ORCID: 0009-0002-7273-3046

Barkhatova A.N.

Mental Health Research Center

ORCID: 0000-0003-3805-332X

Berezkin A.S.

Mental Health Research Centre

ORCID: 0000-0002-3675-3077

Sorokin S.A.

Mental Health Research Center

ORCID: 0000-0001-8654-4858

Received:

28.02.2024

Accepted:

20.03.2024

List of references:

Marneros A, Angst J, eds. Bipolar Disorders: 100 years after manic-depressive insanity. New York; Boston; Dordrecht; London; Moscow: Kluwer Academic Publishers; 2000;483.
Marneros A. Origin and development of concepts of bipolar mixed states. Journal of Affective Disorders. 2001;67(1-3):229-240. https://doi.org/10.1016/S0165-0327(01)00437-2
Mason BL, Brown ES, Croarkin PE. Historical underpinnings of bipolar disorder diagnostic criteria. Behavioral Sciences. 2016;6(3):14. https://doi.org/10.3390/bs6030014
Kannabikh Yu. Istoriya psikhiatrii. M.: Gosudarstvennoe meditsinskoe izdatel’stvo; 1928. (In Russ.).
Angst J, Sellaro R. Historical perspectives and natural history of bipolar disorder. Biological Psychiatry. 2000;48(6):445-457. https://doi.org/10.1016/S0006-3223(00)00909-4
Akiskal HS, Pinto O. The evolving bipolar spectrum prototypes I, II, III, and IV. Psychiatric Clinics of North America. 1999;22(3):517-534. https://doi.org/10.1016/s0193-953x(05)70093-9
Akiskal HS, Hantouche EG, Allilaire JF, et al. Validating antidepressant-associated hypomania (bipolar III): a systematic comparison with spontaneous hypomania (bipolar II). Journal of Affective Disorders. 2003;73(1-2):65-74. https://doi.org/10.1016/S0165-0327(02)00325-7
Mosolov SN, Kostyukova EG. In memory of Professor Akiskala. Sovremennaya Terapiya Psikhicheskikh Rasstroistv. 2021;1:55-56. (In Russ.).
Wehr TA, Goodwin FK. Can antidepressants cause mania and worsen the course of affective illness? American Journal of Psychiatry. 1987;144(11):1403-1411. https://doi.org/10.1176/ajp.144.11.1403
Himmelhoch JM, Thase ME, Mallinger AG, et al. Tranylcypromine versus imipramine in anergic bipolar depression. American Journal of Psychiatry. 1991;148(7):910-916. https://doi.org/10.1176/ajp.148.7.910
Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. British Journal of Psychiatry. 2006;189:124-131. https://doi.org/10.1192/bjp.bp.105.013045
Frye MA, Helleman G, McElroy SL, et al. Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. American Journal of Psychiatry. 2009;166(2):164-172. https://doi.org/10.1176/appi.ajp.2008.08030322
Amsterdam JD, Shults J. Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: A randomized, double-blind, placebo-substitution study. American Journal of Psychiatry. 2010;167(7):792-800. https://doi.org/10.1176/appi.ajp.2009.09020284
Rowland TA, Marwaha S. Epidemiology and risk factors for bipolar disorder. Therapeutic Advances in Psychopharmacology. 2018;8(9):251-269. https://doi.org/10.1177/2045125318769235
Miller S, Dell’Osso B, Ketter TA. The prevalence and burden of bipolar depression. Journal of Affective Disorders. 2014;169(suppl 1):3-11. https://doi.org/10.1016/S0165-0327(14)70003-5
Kupka RW, Altshuler LL, Nolen WA, et al. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disorders. 2007;9(5):531-535. https://doi.org/10.1111/j.1399-5618.2007.00467.x
Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Archives of General Psychiatry. 2002;59(6):530-537. https://doi.org/10.1001/archpsyc.59.6.530
Tondo L, Vázquez GH, Baldessarini RJ. Depression and mania in bipolar disorder. Current Neuropharmacology. 2017;15(3):353-358. https://doi.org/10.2174/1570159X14666160606210811
Petrova NN. Bipolar affective disorder. New possibilities of therapy. Sovremennaya Terapiya Psikhicheskikh Rasstroistv. 2022;1:45-55. (In Russ.). https://doi.org/10.21265/PSYPH.2022.60.1.005
Mosolov SN, Kostyukova EG, Ushkalova AV, et al. Algorithms for biological therapy of bipolar affective disorder. Sovremennaya Terapiya Psikhicheskikh Rasstroistv. 2013;4:31-39. (In Russ.).
Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Archives of General Psychiatry. 2003;60(11):1079-1088. https://doi.org/10.1001/archpsyc.60.11.1079
Detke HC, Delbello MP, Landry J, et al. Olanzapine/fluoxetine combination in children and adolescents with bipolar depression: A randomized, double-blind, placebo-controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry. 2015;54(3):217-224. https://doi.org/10.1016/j.jaac.2014.12.012
Selle V, Schalkwijk S, Vázquez GH, et al. Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium, and second-generation antipsychotics. Pharmacopsychiatry. 2014;47(2):43-52. https://doi.org/10.1055/s-0033-1363258
Maneeton N, Maneeton B, Srisurapanont M, et al. Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials. BMC Psychiatry. 2012;12:160. https://doi.org/10.1186/1471-244X-12-160
Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. The Journal of Clinical Psychiatry. 1999;60(2):79-88. https://doi.org/10.4088/jcp.v60n0203
Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomized trials. British Journal of Psychiatry. 2009;194(1):4-9. https://doi.org/10.1192/bjp.bp.107.048504
Pikalov A, Tohen M, Tsai J, et al. Efficacy of lurasidone in bipolar depression: pooled results of two adjunctive studies with lithium or valproate. Bipolar Disorders. 2016;18:178.
Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression. The New England Journal of Medicine. 2007;356(17):1711-1722. https://doi.org/10.1056/NEJMoa064135
Ghaemi SN, Wingo AP, Filkowski MA, et al. Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks. Acta Psichiatrica Scandinavica. 2008;118(5):347-356. https://doi.org/10.1111/j.1600-0447.2008.01257.x
Sidor MM, Macqueen GM. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. The Journal of Clinical Psychiatry. 2010;72(2):156-167. https://doi.org/10.4088/JCP.09r05385gre
Perlis RH, Ostacher MJ, Goldberg JF, et al. Transition to Mania During Treatment of Bipolar Depression. Neuropsychopharmacology. 2010;35(13):2545-2552. https://doi.org/10.1038/npp.2010.122
McGirr A, Vohringer PA, Ghaemi SN, et al. Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials. The Lancet Psychiatry. 2016;3(12):1138-1146. https://doi.org/10.1016/S2215-0366(16)30264-4
Potanin SS, Morozova MA. Is the prescription of antidepressants for bipolar depression justified from the point of view of evidence-based medicine??. Psikhiatriya. 2020;18(2):51-60. (In Russ.). https://doi.org/10.30629/2618-6667-2020-18-2-51-60
Wichniak A, Jarkiewicz M, Okruszek Ł, et al. Low Risk for Switch to Mania during Treatment with Sleep Promoting Antidepressants. Pharmacopsychiatry. 2015;48(03):83-88. https://doi.org/10.1055/s-0034-1396802
Viktorin A, Lichtenstein P, Thase M, et al. The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. American Journal of Psychiatry. 2014;171(10):1067-1073. https://doi.org/10.1176/appi.ajp.2014.13111501
Tondo L, Vázquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatrica Scandinavica. 2010;121(6):404-414. https://doi.org/10.1111/j.1600-0447.2009.01514.x
Gorwood P, Richard-Devantoy S, Sentissi O, et al. The number of past manic episodes is the best predictor of antidepressant-emergent manic switch in a cohort of bipolar depressed patients. Psychiatry Research. 2016;240:288-294. https://doi.org/10.1016/j.psychres.2016.04.071
Frye MA, McElroy SL, Prieto ML, et al. Clinical risk factors and serotonin transporter gene variants associated with antidepressant-induced mania. The Journal of Clinical Psychiatry. 2015;76(2):174-180. https://doi.org/10.4088/JCP.14m09127
Scott J, Brichant-Petitjean C, Etain B, et al. A re-examination of antidepressant treatment-emergent mania in bipolar disorders: evidence of gender differences. Acta Psychiatrica Scandinavica. 2017;135(5):479-488. https://doi.org/10.1111/acps.12728
Melhuish Beaupre LM, Tiwari AK, Gonçalves VF, et al. Antidepressant-Associated Mania in Bipolar Disorder: A Review and Meta-analysis of Potential Clinical and Genetic Risk Factors. Journal of Clinical Psychopharmacology. 2020;40(2):180-185. https://doi.org/10.1097/JCP.0000000000001186
Mundo E, Walker M, Cate T, et al. The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings. Archives of General Psychiatry. 2001;58(6):539-544. https://doi.org/10.1001/archpsyc.58.6.539
Leverich GS, Altshuler LL, Frye MA, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Archives of General Psychiatry. 2006;163(2):232-239. https://doi.org/10.1176/appi.ajp.163.2.232
Goldberg JF, Whiteside JE. The association between substance abuse and antidepressant-induced mania in bipolar disorder: a preliminary study. The Journal of Clinical Psychiatry. 2002;63(9):791-795. https://doi.org/10.4088/jcp.v63n0907
Aleksandrov AA. Principles of therapy for bipolar depression. Vestnik BPA. 2007;12:45-55. (In Russ.).
Filippis RD, Carbone EA, D’Angelo M, et al. The mediation role of impulsivity between childhood trauma and dissociative symptomatology in bipolar disorder. Rivista di Psichiatria. 2023;58(2):84-92. https://doi.org/10.1708/4022.39978
Joas E, Jonsson L, Viktorin A, et al. Effect of CYP2C19 polymorphisms on antidepressant prescription patterns and treatment emergent mania in bipolar disorder. The Pharmacogenomics Journal. 2023;23(1):28-35. https://doi.org/10.1038/s41397-022-00294-4
Sánchez-Iglesias S, García-Solaesa V, García-Berrocal B, et al. Role of pharmacogenetics in improving the safety of psychiatric care by predicting the potential risks of mania in CYP2D6 poor metabolizers diagnosed with bipolar disorder. Medicine. 2016;95(6):e2473-e2473. https://doi.org/10.1097/MD.0000000000002473
Beaupre LM, Zai CC, Tiwari AK, et al. CYP2D6 metabolizer status and HTTLPR variant of SLC6A4 associated with T antidepressant-induced mania in bipolar disorder. Personalized Medicine in Psychiatry. 2019;13-14. https://doi.org/10.1016/J.PMIP.2018.11.003
Zai CC, Squassina A, Tiwari AK, et al. A genome-wide association study of antidepressant-induced mania. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2023;127:110800. https://doi.org/10.1016/j.pnpbp.2023.110800
Nuñez NA, Coombes BJ, Melhuish Beaupre L, et al. Antidepressant-Associated Treatment Emergent Mania: A Meta-Analysis to Guide Risk Modeling Pharmacogenomic Targets of Potential Clinical Value. Journal of Clinical Psychopharmacology. 2023;43(5):428-433. https://doi.org/10.1097/JCP.0000000000001747
Gardea-Resendez M, Coombes BJ, Veldic M, et al. Antidepressants that increase mitochondrial energetics may elevate risk of treatment-emergent mania. Molecular Psychiatry. 2023;28:1020-1026. https://doi.org/10.1038/s41380-022-01888-x
Demontis F, Serra F, Serra G. Antidepressant-induced Dopamine Receptor Dysregulation: A Valid Animal Model of Manic-Depressive Illness. Current Neuropharmacology. 2017;15(3):417-423. https://doi.org/10.2174/1570159X14666160715165648
Serra G, Collu M, DAquila PS, et al. Possible role of dopamine D1 receptor in the behavioural supersensitivity to dopamine agonists induced by chronic treatment with antidepressants. Brain Research. 1990;527(2):234-243. https://doi.org/10.1016/0006-8993(90)91142-4
DAquila PS, Peana AT, Panin F, et al. Reversal of antidepressant-induced dopaminergic behavioural supersensitivity after long-term chronic imipramine withdrawal. European Journal of Pharmacology. 2003;458(1-2):129-134. https://doi.org/10.1016/S0014-2999(02)02731-0
DAquila PS, Panin F, Serra G. Long-term imipramine withdrawal induces a depressive-like behaviour in the forced swimming test. European Journal of Pharmacology. 2004;492(1):61-63. https://doi.org/10.1016/j.ejphar.2004.04.008
DAquila PS, Collu M, Gessa GL, et al. Dizocilpine prevents the enhanced locomotor response to quinpirole induced by repeated electroconvulsive shock. European Journal of Pharmacology. 1997;330(1):11-14. https://doi.org/10.1016/S0014-2999(97)01019-4
DAquila PS, Sias A, Gessa GL, et al. The NMDA receptor antagonist MK-801 prevents imipramine-induced supersensitivity to quinpirole. European Journal of Pharmacology. 1992;224(2-3):199-202. https://doi.org/10.1016/0014-2999(92)90805-E
Demontis F, Falconi M, Canu D, et al. Memantine prevents bipolar-like behavior induced by chronic treatment with imipramine in rats. European Journal of Pharmacology. 2015;752:49-54. https://doi.org/10.1016/j.ejphar.2015.01.041
DAquila PS, Peana AT, Tanda O, et al. Carbamazepine prevents imipramine-induced behavioural sensitization to the dopamine D(2)-like receptor agonist quinpirole. European Journal of Pharmacology. 2001;416(1-2):107-111. https://doi.org/10.1016/S0014-2999(01)00876-7
DAquila PS, Panin F, Serra G. Chronic valproate fails to prevent imipramine-induced behavioural sensitization to the dopamine D2-like receptor agonist quinpirole. European Journal of Pharmacology. 2006;535(1-3):208-211. https://doi.org/10.1016/j.ejphar.2006.02.016
DAquila PS, Collu M, Devoto P, et al. Chronic lithium chloride fails to prevent imipramine-induced sensitization to the dopamine D(2)-like receptor agonist quinpirole. European Journal of Pharmacology. 2000;395(2):157-160. https://doi.org/10.1016/S0014-2999(00)00189-8
Kim BH, Kim SH, Han C, et al. Antidepressant-induced mania in panic disorder: a single-case study of clinical and functional connectivity characteristics. Frontiers in Psychiatry. 2023;14:1205126. https://doi.org/10.3389/fpsyt.2023.1205126
Stoll AL, Mayer PV, Kolbrener M, et al. Antidepressant-associated mania: a controlled comparison with spontaneous mania. American Journal of Psychiatry. 1994;151(11):1642-1645. https://doi.org/10.1176/ajp.151.11.1642
Kukopulos A, Reginaldi D, Laddomada G, et al. Course of the manic-depressive cycle and changes caused by treatments. Pharmacopsychiatry. 1980;13(4):156-167. https://doi.org/10.1055/s-2007-1019628
Altshuler LL, Post RM, Leverich GS, et al. Antidepressant-induced mania and cycle acceleration: a controversy revisited. American Journal of Psychiatry. 1995;152(8):1130-1138. https://doi.org/10.1176/ajp.152.8.1130
Goldberg J. Spontaneous depression versus biphasic cycling. American Journal of Psychiatry. 2001;158(2):325-326. https://doi.org/10.1176/appi.ajp.158.2.325
El-Mallakh RS, Vöhringer PA, Ostacher MM, et al. Antidepressants worsen rapid-cycling course in bipolar depression: A STEP-BD randomized clinical trial. Journal of Affective Disorders. 2015;184:318-321. https://doi.org/10.1016/j.jad.2015.04.054
Bipolyarnoe affektivnoe rasstroistvo: diagnostika i lechenie. Pod red. Mosolova S.N. M.: MEDpress-inform; 2008;384. (In Russ.).
Maj M, Pirozzi R, Magliano L, Bartoli L. The prognostic significance of «switching» in patients with bipolar disorder: a 10-year prospective follow-up study. American Journal of Psychiatry. 2002;159(10):1711-1717. https://doi.org/10.1176/appi.ajp.159.10.1711
Kostyukova EG, Mosolov SN. Modern approaches to the diagnosis, treatment and prevention of depression in bipolar disorder. Sotsial’naya i Klinicheskaya Psikhiatriya. 2003;4:106-114. (In Russ.).
Plans L, Barrot C, Nieto E, et al. Association between completed suicide and bipolar disorder: A systematic review of the literature. Journal of Affective Disorders. 2019;1(242):111-122. https://doi.org/10.1016/j.jad.2018.08.054
Musil R, Zill P, Seemüller F, et al. Genetics of data from a naturalistic study on a large sample of inpatients with a major depressive episode. European Neuropsychopharmacology. 2013;23:663-674. https://doi.org/10.1016/j.euroneuro.2012.08.009

Close metadata